Shares of Sanofi (SNY - Free Report) were down 5.8% in the pre-market trading session on Aug 17, after management announced its decision to discontinue the development of its investigational oral selective estrogen receptor degrader (SERD) candidate, amcenestrant, which was being evaluated for breast cancer.
The decision was based on results from a prespecified interim analysis of the phase III AMEERA-5 study, which evaluated amcenestrant plus Pfizer’s (PFE - Free Report) Ibrance (palbociclib) versus letrozole plus Ibrance in patients with ER+/HER2- advanced breast cancer.An independent data monitoring committee (IDMC) determined that the amcenestrant plus Ibrance combination, when compared to the letrozole plus Ibrance combination arm, failed to achieve the prespecified boundary required to continue the study.
Ibrance is a blockbuster drug marketed by Pfizer, which the FDA has approved for treating HR+, HER2- advanced or metastatic breast cancer in adults. In the first half of 2022, Pfizer recorded $2.6 billion from Ibrance product sales.
Based on this analysis, the IDMC recommended stopping the study and transitioning the study participants to an appropriate standard of care therapy, as determined by their physician. The study did not report any safety concerns among the participants who were administered the amcenestrant plus Pfizer’s Ibrance combination.
While Sanofi continues to review the above data, it has also decided to discontinue all other studies evaluating amcenestrant.
Shares of Sanofi have lost 10.6% in the year so far against the industry’s 0.4% rise.
Earlier this March, Sanofi reported the phase II AMEERA-3 study, evaluating amcenestrant for treating ER+/HER2- advanced or metastatic breast cancer failed to meet the primary endpoint of improvement in progression-free survival.
The failure of a late-stage candidate like amcenestrant puts high pressure on Sanofi, whose sales are currently being driven by Dupixent, a blockbuster drug developed in partnership with Regeneron Pharmaceuticals (REGN - Free Report) . The drug is currently approved for eczema, asthma, chronic rhinosinusitis with nasal polyposis and eosinophilic esophagitis indications.
Currently, Dupixent is the leading driver of growth for both Regeneron and Sanofi. Both REGN and SNY are also evaluating dupilumab in late-stage studies for a broad range of diseases driven by type 2 inflammations like chronic obstructive pulmonary disease, bullous pemphigoid and prurigo nodularis indications, among others. Continued label expansion of the drug has pulled up profits at both Sanofi and Regeneron.
Zacks Rank & Stocks to Consider
Sanofi currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the overall healthcare sector is Sesen Bio , which sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for Sesen Bio’s 2022 bottom line have narrowed from a loss of 44 cents to 43 cents in the past 30 days. Loss estimates for 2023 have narrowed from 35 cents to 1 cent during the same period. Share prices of Sesen Bio have fallen 12.0% in the year-to-date period.
Earnings of Sesen Bio beat estimates in each of the last four quarters, the average surprise being 89.49%. In the last reported quarter, Sesen Bio delivered an earnings surprise of 61.54%.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Shares of Sanofi (SNY - Free Report) were down 5.8% in the pre-market trading session on Aug 17, after management announced its decision to discontinue the development of its investigational oral selective estrogen receptor degrader (SERD) candidate, amcenestrant, which was being evaluated for breast cancer.
The decision was based on results from a prespecified interim analysis of the phase III AMEERA-5 study, which evaluated amcenestrant plus Pfizer’s (PFE - Free Report) Ibrance (palbociclib) versus letrozole plus Ibrance in patients with ER+/HER2- advanced breast cancer.An independent data monitoring committee (IDMC) determined that the amcenestrant plus Ibrance combination, when compared to the letrozole plus Ibrance combination arm, failed to achieve the prespecified boundary required to continue the study.
Ibrance is a blockbuster drug marketed by Pfizer, which the FDA has approved for treating HR+, HER2- advanced or metastatic breast cancer in adults. In the first half of 2022, Pfizer recorded $2.6 billion from Ibrance product sales.
Based on this analysis, the IDMC recommended stopping the study and transitioning the study participants to an appropriate standard of care therapy, as determined by their physician. The study did not report any safety concerns among the participants who were administered the amcenestrant plus Pfizer’s Ibrance combination.
While Sanofi continues to review the above data, it has also decided to discontinue all other studies evaluating amcenestrant.
Shares of Sanofi have lost 10.6% in the year so far against the industry’s 0.4% rise.
Earlier this March, Sanofi reported the phase II AMEERA-3 study, evaluating amcenestrant for treating ER+/HER2- advanced or metastatic breast cancer failed to meet the primary endpoint of improvement in progression-free survival.
The failure of a late-stage candidate like amcenestrant puts high pressure on Sanofi, whose sales are currently being driven by Dupixent, a blockbuster drug developed in partnership with Regeneron Pharmaceuticals (REGN - Free Report) . The drug is currently approved for eczema, asthma, chronic rhinosinusitis with nasal polyposis and eosinophilic esophagitis indications.
Currently, Dupixent is the leading driver of growth for both Regeneron and Sanofi. Both REGN and SNY are also evaluating dupilumab in late-stage studies for a broad range of diseases driven by type 2 inflammations like chronic obstructive pulmonary disease, bullous pemphigoid and prurigo nodularis indications, among others. Continued label expansion of the drug has pulled up profits at both Sanofi and Regeneron.
Zacks Rank & Stocks to Consider
Sanofi currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the overall healthcare sector is Sesen Bio , which sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for Sesen Bio’s 2022 bottom line have narrowed from a loss of 44 cents to 43 cents in the past 30 days. Loss estimates for 2023 have narrowed from 35 cents to 1 cent during the same period. Share prices of Sesen Bio have fallen 12.0% in the year-to-date period.
Earnings of Sesen Bio beat estimates in each of the last four quarters, the average surprise being 89.49%. In the last reported quarter, Sesen Bio delivered an earnings surprise of 61.54%.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Get the latest research report on REGN - FREE
Get the latest research report on SNY - FREE
Get the latest research report on PFE - FREE